Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis

Table 1 Characteristics of Patients Comparing IO-Chemotherapy with Chemotherapy in Included Trials

Source	PD-(L)1 Drug^b	Histology	No. of patients^a		Median age (years)^a	Male (%)^a	Performance status^a		PD-L1 subgroups^a
Source	PD-(L)1 Drug^b	Histology	ITT	As treated	Median age (years)^a	Male (%)^a	ECOG 0 (%)	ECOG 1 (%)	<1% (%)	1–49% (%)	≥50% (%)
KEYNOTE-189 2018 [6]	Pembrolizumab	nonsquamous	410 vs 206	405 vs 202	65 vs 64	62 vs 53	45 vs 39	54 vs 61	31 vs 31	31 vs 28	32 vs 34
IMpower150 2018 [15]	Atezolizumab	nonsquamous	400 vs 400	393 vs 394	63 vs 63	60 vs 60	39 vs 43	60 vs 57	47 vs 50	33 vs 31	20 vs 19
KEYNOTE-021 2016 [5], 2018 [20]	Pembrolizumab	nonsquamous	60 vs 63	59 vs 62	63 vs 63	37 vs 41	40 vs 46	58 vs 54	35 vs 37	32 vs 37	33 vs 27
KEYNOTE-407 2018	Pembrolizumab	squamous	278 vs 281	278 vs 280	65 vs 65	79 vs 84	26 vs 32	74 vs 68	34 vs 35	37 vs 37	26 vs 26
IMpower131 2018 [17]	Atezolizumab	squamous	343 vs 340	334 vs 334	65 vs 65	81 vs 82	34 vs 32	66 vs 68	47 vs 50	38 vs 36	15 vs 14
CheckMate 227 2018 [18]	Nivolumab	suqamous and nonsquamous	177 vs 186	172 vs 185	64 vs 64	73 vs 67	33 vs 31	66 vs 68	100 vs 100	0 vs 0	0 vs 0

^aData presented as “IO-chemotherapy group vs chemotherapy group”
^bPembrolizumab (200 mg, Q3W), Atezolizumab (1200 mg, Q3W), Nivolumab (360 mg, Q3W)
Abbreviation: IO immuno-oncology, ITT intention-to-treat